# EDGAR Filing Document

**Accession Number:** 0001196298
**File Stem:** 0001641172-25-015250
**Filing Date:** 2025-6
**Character Count:** 5260
**Document Hash:** 47e1cf13a6dbb0fda3b5f357431a4477
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-015250.hdr.sgml**: 20250616

**ACCESSION NUMBER**: 0001641172-25-015250

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250616

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250616

**DATE AS OF CHANGE**: 20250616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEPHROS INC
- **CENTRAL INDEX KEY:** 0001196298
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 133971809
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32288
- **FILM NUMBER:** 251050265

**BUSINESS ADDRESS:**
- **STREET 1:** 380 LACKAWANNA PLACE
- **CITY:** SOUTH ORANGE
- **STATE:** NJ
- **ZIP:** 07079
- **BUSINESS PHONE:** 201.343.5202

**MAIL ADDRESS:**
- **STREET 1:** 380 LACKAWANNA PLACE
- **CITY:** SOUTH ORANGE
- **STATE:** NJ
- **ZIP:** 07079

?xml version='1.0' encoding='ASCII'?

**UNITES STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 16, 2025**

**NEPHROS, INC.**

(Exact name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-32288** | **13-3971809** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

---

| |
|:---|
| **380 Lackawanna Place, South Orange, New Jersey 07079** |
| (Address of principal executive offices, including ZIP code) |

---

---

| |
|:---|
| **(201) 343-5202** |
| (Registrant's telephone number, including area code) |

---

**n/a**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, $0.001 par value | NEPH | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.** |

---

On June 16, 2025, Nephros, Inc. (the "Company") held its 2025 Annual Meeting of the Stockholders (the "Annual Meeting"). At the Annual Meeting:

&nbsp;&nbsp;&nbsp;&nbsp;1. Stockholders
 elected to the Company's Board of Directors one nominee, Lisa Nettis, to serve a three-year term expiring in 2028;

2. Stockholders
 ratified the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal
 year ending December 31, 2025; and

3. Stockholders
 approved the compensation of the Company's named executive officers on an advisory (non-binding) basis.

The voting results for each such matter were as follows:

&nbsp;&nbsp;&nbsp;&nbsp;1. Election
 of Director:

---

| | | | |
|:---|:---|:---|:---|
| Nominee: | For: | Withheld: | Broker Non-Votes: |
| Lisa Nettis | 6066124 | 84178 | 2654001 |

---

&nbsp;&nbsp;&nbsp;&nbsp;2. Ratification
 of the appointment of Baker Tilly US, LLP as the Company's independent registered public
 accounting firm for the fiscal year ending December 31, 2025:

---

| | | | |
|:---|:---|:---|:---|
| For: | Against: | Abstain: | Broker Non-Votes |
| 8663982 | 137516 | 2805 | 0 |

---

&nbsp;&nbsp;&nbsp;&nbsp;3. Approval
 of the compensation of the Company's named executive officers on an advisory (non-binding)
 basis:

---

| | | | |
|:---|:---|:---|:---|
| For: | Against: | Abstain: | Broker Non-Votes |
| 6078954 | 41762 | 29586 | 2654001 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Nephros, Inc.** | **Nephros, Inc.** |
| Dated: June 16, 2025 | By: | */s/ Judy Krandel* |
|  |  | Judy Krandel |
|  |  | Chief Financial Officer |

---